Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM
Original Article from The New England Journal of Medicine — Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
Original Article from The New England Journal of Medicine — Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
Objectives Although controversial, recent data suggest nighttime versus daytime laparoscopic cholecystectomy (LC) have comparable outcomes. Laparoscopic common bile duct exploration (LCBDE) for choledocholithiasis decreases length…
Mayo Clinic researchers have developed a new scoring tool that links Alzheimer’s disease subtypes with age of onset and the […]
Ischemic heart disease (IHD) is the leading cause of morbidity and mortality in both genders; however, young women fare the worst, likely reflecting the more…
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived prod…
Interventionalists say it’s now time to make a dent in the complication rate, whether by strict protocols or smaller devices.
Going forward, data from these kinds of studies could increasingly be used by AI to help personalize therapy for HF patients, an editorial suggests.
Left Ventricular Assist Devices buy precious time for patients on heart transplant waiting lists.
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived prod…
AbstractBackground and Aims. APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that are actively pursued as pharmacological targets to treat dyslipidemi
A 47-year-old man presented with 2-day history of weakness and fever. Laboratory studies showed pancytopenia. A bone marrow biopsy showed promyelocytes with abundant intracellular rods.